



2024

# Taipei International Breast Cancer Symposium

台北國際乳癌研討會

## Speech Abstract

Topic:

**Cardio-Oncology: Protecting the Heart as Curative Breast Cancer Treatment**

Abstract

As the landscape of breast cancer treatment evolves, the focus on long-term survivorship and quality of life becomes increasingly imperative. Cardio-Oncology emerges as a pivotal discipline at the intersection of cardiology and oncology, aimed at mitigating the adverse cardiovascular effects of cancer therapies.

The advent of cancer therapy has significantly improved patient outcomes, yet it has brought forth a concerning side effect known as Cancer Therapy Related Cardiovascular Dysfunction (CTRCD). Defined as a reduction of Left Ventricular Ejection Fraction (LVEF) greater than 10% to a level below 50%, CTRCD is often induced by various cancer drugs including anthracyclines, trastuzumab, hormone therapy, tyrosine kinase inhibitors, and CDK4/6 inhibitors.

There are some proposed diagnostic tools for early detection and risk assessment. Techniques such as echocardiography, nuclear cardiac imaging (MUGA), cardiac magnetic resonance imaging, and cardio-biomarkers like Troponin I and BNP play pivotal roles in timely identification, enabling proactive treatment interventions. By leveraging these tools, clinicians can tailor treatment regimens, mitigate cardiovascular risks, and initiate timely cardio-protective measures, thus enhancing patient outcomes and minimizing morbidity.

As for cancer drug with less cardiotoxicity, the synthesis of clinical evidence and real-world insights will spotlight the efficacy of liposomal doxorubicin in breast cancer treatment. While demonstrating comparable efficacy to conventional anthracyclines such as doxorubicin and epirubicin, liposomal doxorubicin notably mitigates cardiotoxicity, offering a promising avenue for safe administration without compromising therapeutic outcomes. This segment will explore practical strategies for integrating liposomal doxorubicin into breast cancer treatment protocols, emphasizing its potential to optimize patient care while minimizing cardiovascular risks.

In essence, the principles of Cardio-Oncology empowers clinicians to navigate the complex interplay between cancer therapy and cardiovascular health, thereby enhancing the holistic care and well-being of breast cancer survivors.